CannaPharmaRX, Inc.

CPMD

US13765D1090

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 20:41:11 07/06/2024 BST			5-day change	1st Jan Change
0.0157 ^USD	+12.14%		+13.77%	+823.53%

06-04	CannaPharmaRX, Inc. Executes Multi-Year Supply Agreement with ICAN Green S.A. de C.V to Create Distribution Network in the Latin Americas	CI
06-04	CannaPharmaRX, Inc. Receives First Purchase Order	CI

Cannapharmarx, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

August 16, 2021 at 08:13 pm

CannaPharmaRX, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 796,080 compared to USD 787,484 a year ago. Net loss was USD 1.665 million compared to USD 1.472 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.04 a year ago. For the half year, operating loss was USD 1.517 million compared to USD 3.357 million a year ago. Net loss was USD 467,435 compared to USD 5.687 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.15 a year ago.

Latest news about CannaPharmaRX, Inc.

CannaPharmaRX, Inc. Executes Multi-Year Supply Agreement with ICAN Green S.A. de C.V to Create Distribution Network in the Latin Americas	06-04	CI
CannaPharmaRX, Inc. Receives First Purchase Order	06-04	CI
CannaPharmaRX, Inc. Announces CEO Changes	06-04	CI
CannaPharmaRX, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05-16	CI
CannaPharmaRX, Inc. Receives First Purchase Order and Begins Shipment of Product	03-14	CI
CannaPharmaRX, Inc. Executes Multi-Year Supply Agreement with Ican to Create Distribution Network in the Latin Americas	03-05	CI
CannaPharmaRx, Inc Enters into Strategic Supply Agreement with Cantek Holdings	02-16	CI
CannaPharmaRX, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-17	CI
CannaPharmaRX, Inc. Announces Executive Changes	13/10/23	CI
CannaPharmaRX, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	13/10/23	CI
CannaPharmaRX, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	22/09/23	CI
CannaPharmaRX, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/09/23	CI
CannaPharmaRx Expands Board of Directors	25/08/23	CI
CannaPharmaRX, Inc. Announces CEO Changes	23/06/23	CI
CannaPharmaRX, Inc. Signs Supply Agreement with Y.S.A Holdings for Up to $15 Million Annually of Commercial Cannabis	30/03/23	CI
CannaPharmaRX, Inc. completed the acquisition of LTB Management LLC.	20/03/23	CI
CannaPharmaRX, Inc. agreed to acquire LTB Management LLC.	20/02/23	CI
CannaPharmaRx Receives Canada Revenue Agency License As Final Step to Bringing Facility Into Production With Annual Revenues of Over $30 Million Expected	11/01/23	CI
CannaPharmaRx, Inc Receives Cultivation License from Health Canada and Projects 2023 Revenue over $30 Million	21/12/22	CI
CannaPharmaRX, Inc. Provides Revenue Guidance for the Full Year 2023	21/12/22	CI
CannaPharmaRx, Inc. Receives Cultivation License from Health Canada	21/12/22	CI
CannaPharmaRX, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	21/11/22	CI
CannaPharmaRX, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22/08/22	CI
CannaPharmaRX, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	23/05/22	CI
CannaPharmaRX, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	15/04/22	CI

Chart CannaPharmaRX, Inc.

Duration

Period

More charts

Company Profile

CannaPharmaRx, Inc. is focused on the acquisition and development of state-of-the-art cannabis growing facilities in Canada. The Company is engaged in producing customizable medical cannabis and craft products. Its business strategy is to produce a high quality and low-cost production of cannabis through the development, acquisition, and enhancement of existing facilities. The Company is focused on operating high-quality facilities utilizing the latest technology in combined heat and power generation to ensure being a low-cost producer of cannabis. The Company also offers a range of services to assist with cannabis inventory management.

Sector

Pharmaceuticals

Calendar

18/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CANNAPHARMARX, INC.	+823.53%	9.16M
ELI LILLY AND COMPANY	+45.82%	754B
NOVO NORDISK A/S	+40.95%	630B
JOHNSON & JOHNSON	-6.16%	352B
MERCK & CO., INC.	+19.86%	331B
ABBVIE INC.	+9.32%	298B
ASTRAZENECA PLC	+18.45%	250B
NOVARTIS AG	+11.88%	217B
ROCHE HOLDING AG	-0.78%	216B
AMGEN INC.	+5.90%	164B

Other Pharmaceuticals